TIDMCREO
RNS Number : 3730A
Creo Medical Group PLC
22 January 2024
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Award of Shares under Share Incentive Plan, Director Dealings,
Issue of Equity and TVR
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, implemented an
HMRC approved Share Incentive Plan ("SIP") during 2020 which is
available to all of the Company's UK based employees, including
Directors.
Under the SIP, shares are acquired in four ways:
-- Partnership Shares where an employee can spend up to a
GBP1,800 or 10% of their pre-tax income, whichever is the
lower;
-- Matching Shares, where Creo can give up to two free Matching
Shares for each Partnership Share bought. The plan requires
employees to remain in employment for three years to benefit from
the Matching Shares;
-- Free Shares, where Creo can give up to GBP3,600 of free shares in any tax year; and
-- Dividend Shares where additional shares can be bought with any dividends paid.
The Company has been notified that Fiduchi Trustees (UK)
Limited, the independent trustee of the SIP, acquired, in
accordance with the SIP's rules and on behalf of SIP participants,
171,050 ordinary shares in the Company ("Ordinary Shares"), at a
price of GBP0.435 per Ordinary Share on 15 January 2024 to meet its
obligations under the SIP. Under the terms of the SIP, the Company
is required to issue to the SIP, two Ordinary Shares in the Company
for each Partnership Share purchased, being 225,024 new Ordinary
Shares (having taken into account 117,076 ordinary shares held by
the Trust which were previously allocated to employees who ceased
employment before the shares had vested). These new Ordinary Shares
will be held by Fiduchi Trustees (UK) Limited as trustee of the
SIP.
Craig Gulliford, Richard Rees and Christopher Hancock, executive
directors of the Company (the "Participating Directors") have
received Partnership Shares at a price of GBP0.435 per share and
Matching Shares at a price of GBP0.001 per share in accordance with
terms of the SIP (the "Transaction"). Following this the
Participating Directors' shareholdings in the Company are as set
out in the table below:
Director Total number of Ordinary Total number of Ordinary
Shares purchased or awarded Shares held post Transaction
under SIP
Craig Gulliford,
CEO 6,207 1,644,527[1]
----------------------------- ------------------------------
Richard Rees, CFO 6,207 2,819,963
----------------------------- ------------------------------
Christopher Hancock,
CTO 6,207 4,816,413
----------------------------- ------------------------------
Accordingly, the Company announces that it has made an
application for 225,024 new Ordinary Shares to be admitted to
trading on AIM. It is expected that admission will take place on 26
January 2024. Following the allotment and issue, the Company's
issued share capital consists of 361,476,442 Ordinary Shares. The
Company does not hold any shares in Treasury. As such the total
number of shares in issue with voting rights is 361,476,442.
Total Voting Rights (TVR)
The above figure of 361,476,442 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
The notifications below, made in accordance with the
requirements of the Market Abuse Regulation, provide further detail
in relation to the award of the SIP Shares to the Participating
Directors.
[1] This figure includes 1,000,000 shares held by Mr Gulliford's
wife.
Enquiries:
Creo Medical Group plc www.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cavendish Capital Markets Limited +44 (0)20 7220 0500
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson (Sales)
Deutsche Numis (Joint Broker)
Freddie Barnfield / Duncan Monteith
/ Euan Brown +44 (0)20 7260 1000
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Sam Allen / Mob: +44 (0)7980 541 893 / +44 (0)7502
Phillip Marriage 558 258 / +44 (0)7867 984 082
About Creo Medical
Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices,
bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the
development and commercialisation of a suite of electrosurgical
medical devices, each enabled by CROMA, powered by Kamaptive. The
Group has developed the CROMA powered by Kamaptive full-spectrum
adaptive technology to optimise surgical capability and patient
outcomes. Kamaptive is a seamless, intuitive integration of
multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection,
coagulation, and ablation of tissue. Kamaptive technology provides
clinicians with increased flexibility, precision and controlled
surgical solutions. CROMA currently delivers bipolar radiofrequency
("RF") energy for precise localised cutting and focused high
frequency microwave ("MW") energy for controlled coagulation and
ablation via a single accessory port. This technology, combined
with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and
controlled clinical solutions. The Directors believe the Company's
technology can impact the landscape of surgery and endoscopy by
providing a safer, less invasive and more cost-efficient option for
procedures.
For more information, please refer to the website
www.creomedical.com
1. Details of PDMR
a) Name Craig Gulliford
------------------------- ----------------------------------------
b) Position / status CEO
------------------------- ----------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- ----------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- ----------------------------------------
b) Nature of the Purchase of Ordinary Shares under Share
transaction Incentive Plan
------------------------- ----------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.435 2,069
----------
------------------------- ----------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- ----------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- ----------------------------------------
1. Details of PDMR
a) Name Craig Gulliford
------------------------- -----------------------------------------------
b) Position / status CEO
------------------------- -----------------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- -----------------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- -----------------------------------------------
b) Nature of the Award of Ordinary Shares under Share Incentive
transaction Plan
------------------------- -----------------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.001 4,138
----------
------------------------- -----------------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- -----------------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- -----------------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- -----------------------------------------------
1. Details of PDMR
a) Name Richard Rees
------------------------- ----------------------------------------
b) Position / status CFO
------------------------- ----------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- ----------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- ----------------------------------------
b) Nature of the Purchase of Ordinary Shares under Share
transaction Incentive Plan
------------------------- ----------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.435 2,069
----------
------------------------- ----------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- ----------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- ----------------------------------------
1. Details of PDMR
a) Name Richard Rees
------------------------- -----------------------------------------------
b) Position / status CFO
------------------------- -----------------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- -----------------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- -----------------------------------------------
b) Nature of the Award of Ordinary Shares under Share Incentive
transaction Plan
------------------------- -----------------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.001 4,138
----------
------------------------- -----------------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- -----------------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- -----------------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- -----------------------------------------------
1. Details of PDMR
a) Name Christopher Hancock
------------------------- ----------------------------------------
b) Position / status CTO
------------------------- ----------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- ----------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- ----------------------------------------
b) Nature of the Purchase of Ordinary Shares under Share
transaction Incentive Plan
------------------------- ----------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.435 2,069
----------
------------------------- ----------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- ----------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- ----------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- ----------------------------------------
1. Details of PDMR
a) Name Christopher Hancock
------------------------- -----------------------------------------------
b) Position / status CTO
------------------------- -----------------------------------------------
c) Initial notification Initial notification
/ amendment
------------------------- -----------------------------------------------
2. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Ordinary Shares
the financial
instrument
------------------------- -----------------------------------------------
b) Nature of the Award of Ordinary Shares under Share Incentive
transaction Plan
------------------------- -----------------------------------------------
c) Price(s) and volume(s) Prices Volume(s)
GBP0.001 4,138
----------
------------------------- -----------------------------------------------
d) Aggregated information N/A - Single transaction
Aggregated volume
Price
------------------------- -----------------------------------------------
e) Date of the 2024-01-19 GMT
transaction
------------------------- -----------------------------------------------
f) Place of the transaction London Stock Exchange
------------------------- -----------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEBBMMTMTMTTBI
(END) Dow Jones Newswires
January 22, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Creo Medical (LSE:CREO)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Creo Medical (LSE:CREO)
Storico
Da Gen 2024 a Gen 2025
